CD8A and neoplasm: Melanoma tumors that acquire BRAF/MEK inhibitor resistance are shown to display a mesenchymal phenotype and an immunologically-cold, M2 macrophage signature with decreased infiltration of cytotoxic CD8 T cells compared to the pre-treatment tumor 109, 110.